Botulinum toxin type-A practice in bruxism cases

Bolayir G., Bolayir E., Coskun A., Oezdemir A. K., Topaktas S.

NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, cilt.12, sa.1, ss.43-46, 2005 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 1
  • Basım Tarihi: 2005
  • Dergi Adı: NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.43-46
  • Anahtar Kelimeler: bruxism, BTX-A botulinum toxin-A, VAS visual analogue score, masseter muscle, TEMPOROMANDIBULAR DISORDERS, MUSCLE, INJECTION
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Bruxism is a parafunctional disease developing diurnal and/or nocturnally. Sleep bruxism has been related to craniomandibular disorders including headaches, temporomandibular joint discomfort and muscles aches, premature loss of teeth due to excessive attrition and mobility. Splint and muscle relaxants are used in the treatment of bruxism. In this study, we have used BTX-A type A (DYSPORT) as a new treatment approach in patients with bruxism. 12 individuals with sleep bruxism (SB) (7 female, 5 male; an average 27 years of age) were treated in this study. An average of 50 U of Dysport has been injected to the painful masseter muscles of individuals included in our study. A decrease has been detected in the existing pain scores in masseter muscles in cases with bruxism. It has also been observed that individuals have left their bruxism habits. As a result, we can conclude that BTX-A type injection would be a useful treatment method in cases with bruxism.